We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

25 hedge funds and large institutions have $21.9M invested in Protara Therapeutics in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0% more ownership

Funds ownership: 1.26% → 1.27% (+0%)

2% less capital invested

Capital invested by funds: $22.4M → $21.9M (-$500K)

17% less funds holding

Funds holding: 30 → 25 (-5)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
25
Holders Change
-5
Holders Change %
-16.67%
% of All Funds
0.57%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
1
Increased
6
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$164K
2
BFM
Boothbay Fund Management
New York
+$116K
3
Deutsche Bank
Deutsche Bank
Germany
+$84.8K
4
BlackRock
BlackRock
New York
+$62.2K
5
DS
DRW Securities
Illinois
+$46.6K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$150K
2
PI
Pharmstandard International
Luxembourg
-$140K
3
Citadel Advisors
Citadel Advisors
Florida
-$45K
4
VF
Virtu Financial
New York
-$37K
5
ARTA
A.R.T. Advisors
New York
-$32K
Name Holding Trade Value Shares
Change 		Change in
Stake
A
1
Abingworth
United Kingdom
$4.84M – – –
PI
2
Pharmstandard International
Luxembourg
$3.94M -$140K -1,503 -4%
RCM
3
RA Capital Management
Massachusetts
$3.28M – – –
DM
4
Deerfield Management
New York
$3M – – –
MAM
5
MPM Asset Management
Massachusetts
$2.41M – – –
PA
6
Perceptive Advisors
New York
$819K – – –
DVC
7
Deer VII & Co
New York
$772K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$751K +$164K +1,759 +30%
BBA
9
Baker Bros. Advisors
New York
$732K – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$352K -$150K -1,613 -31%
BFM
11
Boothbay Fund Management
New York
$196K +$116K +1,249 +166%
DS
12
DRW Securities
Illinois
$181K +$46.6K +500 +37%
FCI
13
Financial Counselors Inc
Kansas
$123K – – –
Deutsche Bank
14
Deutsche Bank
Germany
$89K +$84.8K +910 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$79K – – –
BlackRock
16
BlackRock
New York
$74K +$62.2K +667 +725%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$45K – – –
Northern Trust
18
Northern Trust
Illinois
$45K +$4.75K +51 +13%
PAM
19
Panagora Asset Management
Massachusetts
$38K – – –
RJFSA
20
Raymond James Financial Services Advisors
Florida
$30K – – –
Mariner
21
Mariner
Kansas
$25K – – –
Acadian Asset Management
22
Acadian Asset Management
Massachusetts
$13K – – –
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$9K – – –
SPIA
24
Steward Partners Investment Advisory
New York
$5K – – –
UBS Group
25
UBS Group
Switzerland
$5K +$4.85K +52 +1,733%
1
2

TARA Hedge Fund Activity: Q2 2018 in Review

25 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2018, worth a combined $21.9M — down 2.2% from $22.4M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of TARA and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $164K. The largest seller was Vanguard Group, cutting an estimated $150K.

  • 25 institutional investors held Protara Therapeutics (TARA) as of Q2 2018, down from 30 in Q1 2018.
  • Funds reported $21.9M of Protara Therapeutics stock for Q2 2018, down 2.2% quarter-over-quarter.
  • 1 fund opened new Protara Therapeutics positions in Q2 2018 and 6 closed out, a net change of -5 holders.
  • The largest Protara Therapeutics buyer in Q2 2018 was Renaissance Technologies, an estimated $164K added.
  • The largest Protara Therapeutics seller in Q2 2018 was Vanguard Group, an estimated $150K sold.

Based on aggregated 13F filings for Q2 2018.